Cyclacel Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of oncology drugs. Its flagship product, CYC065, is a potential game-changer in the treatment of various cancers. With its 6% Convertible Preferred Stock, the company offers investors a unique opportunity to participate in its growth and success.
Notification